BioNTech total assets 2017-2024

Published by
Matej Mikulic,
Mar 24, 2025

On November 9th, 2020, German biotech company BioNTech in cooperation with U.S. pharma giant Pfizer were the first to announce a proven COVID-19 vaccine to be ready for mass production by year-end. In 2024, total assets of biotech company BioNTech SE stood at some 22.5 billion U.S. dollars. This statistic illustrates the total assets of BioNTech SE from 2017 to 2024.

Total assets of BioNTech SE from 2017 to 2024 (in million euros)

CharacteristicTotal assets in million euros
2024 22,529.7
2023 23,006.3
2022 23,279.1
2021 15,830.8
2020 2,318.6
2019 797.6
2018 653
2017 374.7
Showing entries 1 to 8 (8 entries in total)
Created with Highcharts 7.2.2Total assets in million euros374.7374.7653653797.6797.62,318.62,318.615,830.815,830.823,279.123,279.123,006.323,006.322,529.722,529.720172018201920202021202220232024
05,00010,00015,00020,00025,00030,000

© Statista 2025
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

March 2025

Region

Worldwide, Germany

Survey time period

2017 to 2024

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Leading companies trust Statista:
paypal google adobe pg samsung telekom

Related reports: Available to download in PDF or PPTX format

All datain one format
All data
in one format
Coronavirus: the pharma and medtech response
  • 55 page/s
  • English
  • pptx
  • Detailed references

Everything on "Coronavirus: the pharma and medtech response" in one document: edited and divided into chapters, including detailed references.

Go to report
Further reports
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on " BioNTech "

Other statistics that may interest you BioNTech

Overview

5

Key figures

5

Competitors

5

COVID-19 vaccine

6

Further related statistics

13

Discover Statista

Need help with using Statista for your research? Tutorials and first steps

Further Content: You might find this interesting as well

Statistics

Topics

BioNTechBiotech drugsmRNA technologyCoronavirus disease (COVID-19) pandemicCoronavirus (COVID-19) in the U.S.
Do you have any questions about our business solutions?

We provide you with detailed information about our Professional Account.

Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.